Stereotaxis (STXS) Earnings Date & Reports

Key Takeaways

• Stereotaxis is scheduled to report its third quarter 2026 results after the U.S. market close on Tuesday, November 10, 2026.
• Consensus estimates point to a net loss of roughly $0.05 per share on revenue near $9.6 million.
• Management has guided to about $7 million in recurring revenue and $3 million in system revenue for the quarter.
• The company is navigating a commercial transition, ramping its MAGiC catheter and GenesisX robot while winding down its legacy Johnson & Johnson relationship.
• Robotic catheter revenue surpassed $1 million in Q2 2026, up 270% sequentially, making it a critical metric for this report.
• Investors will watch whether accelerating catheter adoption can offset softer capital-equipment (system) sales.
• For more information on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages.
• Looking for automated trade ideas? Explore Trending AI Robots to see AI-driven strategies in action.

Earnings Context and Why It Matters

Stereotaxis is a medical technology company that develops robotic systems for minimally invasive endovascular procedures, primarily used in cardiac electrophysiology to treat heart rhythm disorders. This quarter matters because the company is at an early inflection point in a multi-year product transition. Following U.S. FDA (Food and Drug Administration) approval of its MAGiC cardiac ablation catheter in January 2026 and clearance of its Synchrony digital operating room system in April, Stereotaxis completed its acquisition of Robocath in July. The Q3 print will show whether these new products are translating into sustainable revenue growth, a key question as the company works toward its stated goal of cash-flow profitability in the first half of 2027.

Earnings Expectations

Analysts expect Stereotaxis to report a net loss of about $0.05 per share for the third quarter of 2026, roughly in line with the prior quarter's loss. Consensus revenue estimates center near $9.6 million, which would mark meaningful year-over-year growth from the $7.46 million recorded in Q3 2025. Management's own guidance implies total revenue around $10 million, driven by approximately $7 million in recurring revenue and $3 million in system revenue.

These figures are worth watching closely because recent quarters have been uneven. In Q2 2026, the company reported revenue of $7.67 million, down 12% year over year, as a lack of robotic system deliveries weighed on results. EPS came in at a loss of $0.05 per share. The upcoming report should provide a clearer read on whether the new product ecosystem is beginning to offset the wind-down of legacy third-party catheter sales.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities far more efficiently than manual screening. If you are looking to streamline your research process, the AI Screener offers a practical starting point for identifying setups that match your own criteria.

Market Reaction and Investor Sentiment

Sentiment heading into the report reflects both optimism about Stereotaxis's regulatory milestones and caution about near-term execution. The stock has historically been sensitive to revenue trajectory, with Q2 2026 results drawing a modestly negative post-earnings reaction after revenue missed consensus. Key risk factors include production capacity constraints on the MAGiC catheter, which management has said is in higher demand than current supply can meet, and the lingering impact of the Johnson & Johnson transition on recurring revenue. Investors will likely interpret the Q3 numbers through the lens of whether recurring revenue and catheter adoption momentum justify the company's growth narrative.

Forward Outlook and Key Factors to Monitor

Beyond the headline figures, several factors will shape how investors assess Stereotaxis in the quarters ahead. The pace of MAGiC catheter adoption is the most important. Management has indicated that contract manufacturing is expected to exceed 500 catheters per month by year-end, and any commentary on supply expansion will be closely watched.

Capital equipment is another key area. The GenesisX robotic system, which does not require construction for installation in existing catheterization labs, is positioned to reignite system sales. Initial orders and installations of the Synchrony digital operating room are also expected to contribute. Investors should monitor order backlog and installation commentary for signs of durable system demand.

Finally, the company's path to cash-flow profitability remains a central theme. Management has pointed to the first half of 2027 as a target for reaching cash-flow profitability, supported by incremental recurring revenue flowing through to operating profit. Watch for updates on gross margin, operating expense discipline, and cash position, as these will signal whether that timeline remains achievable without additional financing.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations